Compare OneSpan Inc (OSPN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Viatris Inc — how do they compare? OneSpan Inc trades at $15.2 (market cap $571.66M), while Viatris Inc trades at $17.13 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 35.9× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.37%). Which is the better fit depends on your goals.
| OSPN | VTRS | |
|---|---|---|
Market Cap | $571.66M | $20.50B |
Sector | Technology | Health |
52-Week High | $16.32 | $17.59 |
52-Week Low | $10.15 | $8.74 |
Enterprise Value | $529.87M | $32.71B |
Dividend Yield | 3.37% | 2.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
